Brookline Capital Markets Forecasts NBP FY2026 Earnings

Novabridge Biosciences (NASDAQ:NBP) – Analysts at Brookline Capital Markets issued their FY2026 earnings estimates for Novabridge Biosciences in a report issued on Monday, November 2nd. Brookline Capital Markets analyst K. Raja forecasts that the company will post earnings per share of ($0.77) for the year. The consensus estimate for Novabridge Biosciences’ current full-year earnings is ($0.30) per share. Brookline Capital Markets also issued estimates for Novabridge Biosciences’ FY2027 earnings at ($1.31) EPS, FY2028 earnings at ($1.25) EPS, FY2029 earnings at ($1.43) EPS and FY2030 earnings at ($0.92) EPS.

Novabridge Biosciences (NASDAQ:NBP) last announced its quarterly earnings data on Thursday, August 20th. The company reported ($0.16) EPS for the quarter.

Several other equities research analysts have also issued reports on the stock. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Novabridge Biosciences in a research note on Thursday, August 20th. Wall Street Zen upgraded Novabridge Biosciences from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Novabridge Biosciences in a research note on Thursday, August 27th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.00.

Novabridge Biosciences Stock Performance

NBP opened at $1.01 on Thursday. Novabridge Biosciences has a twelve month low of $1.01 and a twelve month high of $5.19. The company’s 50-day moving average price is $1.46 and its two-hundred day moving average price is $2.04.

Insider Transactions at Novabridge Biosciences

In other Novabridge Biosciences news, insider Sean Wuxiong Cao sold 107,978 shares of the company’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $0.74, for a total transaction of $79,903.72. Following the sale, the insider directly owned 266,467 shares of the company’s stock, valued at $197,185.58. This represents a 28.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 119,469 shares of company stock valued at $88,325. Insiders own 22.10% of the company’s stock.

About Novabridge Biosciences

Novabridge Biosciences (NASDAQ: NBP) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel biologic medicines, primarily for the treatment of cancer. Its research and development activities center on immunotherapies designed to activate the immune system or target specific proteins associated with tumor growth and survival.

The company’s pipeline has included investigational antibody-based therapies such as givastomig, a bispecific antibody designed to target Claudin 18.2 and stimulate an immune response through 4-1BB, as well as other programs directed at tumor-associated and immune-regulatory targets.